Please login to the form below

Not currently logged in
Email:
Password:

CAD106

This page shows the latest CAD106 news and features for those working in and with pharma, biotech and healthcare.

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

There is no word yet from Novartis on another of its candidates, anti-amyloid beta vaccine CAD106 (amilomotide), which was being tested in the Generation S1 trial alongside CNP520.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics